CRA provided testimony in support of Masimo in its successful effort to refute monopolization, tying, and other antitrust counterclaims following a competitor’s infringement of its medical device patents. The team was led by Tim Snail and included Sharon Pang, Eyal Dvir, Omeed Alerasool, Ryne Belliston, Carl Hayden, Daniel Ladd, Joseph Marin, Flore Nouvel, and Sarah Black.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...